SCHEMBL1407208

SCHEMBL1407208

CCOC(=O)C1CCN(c2ccc(-c3c4cccc(C(F)(F)F)c4nn3Cc3c(F)cc(F)cc3F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 12/20 0.47
NR1H3 Q13133 12/20 0.47
NR1I2 O75469 2/20 0.46
NR3C1 P04150 2/20 0.46
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
AR P10275 1/20 0.44
RXRA P19793 1/20 0.44
PDK2 Q15119 1/20 0.42
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 2/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407813 0.91 KDM4E (0.44) NR1H2NR1H3NR1I2NR3C1KDM4E
SCHEMBL1407279 0.87 NR1H2 (0.58) NR1H2NR1H3NR1I2NR3C1KDM4E
SCHEMBL1407435 0.86 NR1H2 (0.45) NR1H2NR1H3NR1I2NR3C1KDM4E
SCHEMBL1407326 0.85 NR1H2 (0.61) NR1H2NR1H3NR1I2NR3C1KDM4E
SCHEMBL1407518 0.85 NR1H2 (0.54) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407972 0.85 NR1H2 (0.52) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407423 0.85 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407265 0.84 NR1H2 (0.51) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407392 0.84 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407436 0.84 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NR1I2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.